Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.65 |
| ▸ | CDK2 | P24941 | 9/20 | 0.60 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12953622 | 0.98 | GSK3B (0.65) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12954189 | 0.94 | GSK3B (0.64) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953582 | 0.88 | GSK3B (0.72) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL13122637 | 0.87 | GSK3B (0.67) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953982 | 0.86 | GSK3B (0.72) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12954177 | 0.86 | CDK2 (0.73) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL14572802 | 0.85 | GSK3B (0.71) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12954181 | 0.85 | GSK3B (0.59) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12953627 | 0.85 | GSK3B (0.70) | GSK3BCDK2CCNA2CCNA1CCNE1 | |
| SCHEMBL12954203 | 0.84 | GSK3B (0.76) | GSK3BCDK2CCNA2CCNA1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720882-B1 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2008130570-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130569-A1 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |